General
Preferred name
dexrazoxane
Synonyms
DEXRAZOXANE HYDROCHLORIDE ()
ICRF187 ()
NSC169780 ()
ICRF-187 hydrochloride ()
ADR-529 hydrochloride ()
SB 271046A ()
ICRF-187 ()
ICRF-187 (hydrochloride) ()
ADR-529 (hydrochloride) ()
NSC-169780 (hydrochloride) ()
Dexrazoxane (Hydrochloride) ()
RAZOXANE ()
ADR-529 ()
NSC-169780 ()
ADR-529,Totect, ICRF-187, Zinecard, Cardioxane ()
Dexrazoxane HCl (ICRF-187) ()
SB 271046 hydrochloride ()
DexrazoxaneZinecardTotectICRF-187(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propaneSoluble ICRF (L-isosomer)(S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propaneADR 5292,6-Piperazinedione,4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-2,6-Piperazinedione,4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis- ()
Cardioxane ()
Razoxane, (s)- ()
Razoxane (+)-form ()
Dexrazoxano ()
Razoxane, d- ()
ICRF-187 HYDROCHLORIDE ()
Cardioxan ()
Razoxane hydrochloride, (s)- ()
Totect ()
Savene ()
ADR-529 HYDROCHLORIDE ()
Zinecard ()
Razoxane (+)-form hydrochloride ()
Dexrazoxane HCl ()
P&D ID
PD000493
CAS
1263283-43-7
149003-01-0
24584-09-6
209481-24-3
Tags
available
drug
Approved by
FDA
First approval
1995
Drug indication
Breast cancer
Ewing sarcoma
Leukemia
Chemoprotection
Respiratory tract disease
Drug Status
approved
withdrawn
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Dexrazoxane is an EDTA derivative with iron-chelating activity. (GtoPdb)
DESCRIPTION Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells[1] [2] [3] [4] [5] [6].
PRICE 29
PRICE 56
DESCRIPTION SB 271046 hydrochloride (SB 271046A) is selective, orally active 5-HT6 antagonist (pKi values are 9.02-8.92, 6.35, 6.55, 6.27 at 5-HT6, 5-HT1A, 5-HT1D and D3, and 6.05, 5.95, 5.76, 5.73, 5.62, 5.55, 5.41, 5.39, 5.27 and < 4.99 at 5-HT1B, 5-HT1F, ??1B, 5-HT2C, 5-HT2A, D2, 5-HT2B, 5-HT7, 5-HT4 and 5-HT1E respectively) and is > 200-fold selective over 55 other receptors, enzymes and ion channels. It increases extracellular aspartate and glutamate in the frontal cortex and exhibits anticonvulsant activity (EC50: 0.16 ??M).
DESCRIPTION Dexrazoxane is a cytoprotective drug. It is used to prevent and improve cardiomyopathy associated with doxorubicin treatment for metastatic breast cancer. (Enamine Bioactive Compounds)
DESCRIPTION Dexrazoxane (ICRF-187) is an anticancer drug used to block mitosis and arrest dividing cells. It is an iron chelator and provides cardioprotection against anthracycline toxicity. (TargetMol Bioactive Compound Library)
DESCRIPTION Potent G9a and GLP inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Topoisomerase II inhibitor (Tocriscreen Total)
DESCRIPTION Dexrazoxane hydrochloride is an intracellular iron chelator, which decreases the formation of superoxide radicals, used as a cardioprotective agent. (BOC Sciences Bioactive Compounds)
DESCRIPTION SB 271046 hydrochloride (SB 271046A) is selective, orally active 5-HT6 antagonist (pKi values are 9.02-8.92, 6.35, 6.55, 6.27 at 5-HT6, 5-HT1A, 5-HT1D and D3, and 6.05, 5.95, 5.76, 5.73, 5.62, 5.55, 5.41, 5.39, 5.27 and < 4.99 at 5-HT1B, 5-HT1F, α1B, 5-HT2C, 5-HT2A, D2, 5-HT2B, 5-HT7, 5-HT4 and 5-HT1E respectively) and is > 200-fold selective over 55 other receptors, enzymes and ion channels. It increases extracellular aspartate and glutamate in the frontal cortex and exhibits anticonvulsant activity (EC50: 0.16 μM). (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
0
Compound Sets
29
AdooQ Bioactive Compound Library
A10300
BOC Sciences Bioactive Compounds
dexrazoxane-hydrochloride-cas-149003-01-0-item-59278
Cayman Chemical Bioactives
14632
ChEMBL Approved Drugs
CHEMBL1738
CHEMBL1200778
ChEMBL Drugs
CHEMBL1738
CHEMBL1200778
Drug Repurposing Hub
DrugBank
DB00380
DrugBank Approved Drugs
DB00380
DrugCentral
839
DrugCentral Approved Drugs
839
DrugMAP
DMD7X1O
DrugMAP Approved Drugs
DMD7X1O
Enamine Bioactive Compounds
EBC-26383
Guide to Pharmacology
7330
Mcule NIBR MoA Box Subset
MCULE-5508863882
MedChem Express Bioactive Compound Library
HY-B0581
HY-76201
NCATS Inxight Approved Drugs
048L81261F
NIH Approved Oncology Drugs
442425
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
dexrazoxane
Dexrazoxane-Hydrochloride
TargetMol Bioactive Compound Library
T22305
T4118
The Spectrum Collection
Tocris Bioactive Compound Library
3857
Tocriscreen Total
Withdrawn 2.0
DB00380
External IDs
78
Properties
(calculated by RDKit )
Molecular Weight
268.12
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
0
cLogP
-2.71
TPSA
98.82
Fraction CSP3
0.64
Chiral centers
1.0
Largest ring
6.0
QED
0.54
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
5-HT Receptor
5-HT6
TOP2A, TOP2B
Apoptosis
Ferroptosis
Primary Target
DNA Topoisomerases
MOA
Topoisomerase
Inhibitor
Topoisomerase II inhibitor
chelating agent, topoisomerase inhibitor
Member status
member
Indication
cardiomyopathy
ATC
V03AF02
Therapeutic Class
Anticancer Agents
Pathway
GPCR/G protein
Neuroscience
Source data